The subconjunctival implant of dexamethasone reduces the risk of graft rejection after penetrating keratoplasty.

Published Date: 17 Mar 2023

Dexamethasone subconjunctival implant may be safe and effective in preventing infection in patients after infiltration with a low risk of rejection...

Read Full News

Latest News

Dry Eye Drug Does Well in Study, but FDA Remains Unconvinced

The drug, reproxalap, led to reductions in symptoms of dry eye, but regulators have repeatedly refused to approve it for this condition.

Sarcoid Uveitis: 1 in 3 Achieve Remission, Relapses Rare

Remission is achievable and relapses are uncommon in patients with sarcoid uveitis, although those with swelling in the macular region may experience delayed remission.

Female Eye Doctors Earn Less Across All Ranks

Women in academic ophthalmology earn less than men across all ranks, with a pay-gap over a full career of roughly $1 million, a study finds.

US FDA Declines to Approve Aldeyra's Eye Disorder Drug, Shares Slump

The U.S. Food and Drug Administration declined to approve Aldeyra Therapeutics' drug for a type ⁠of eye disease, the company said on Tuesday, sending its shares plunging...

Light Therapy May Improve Vision in Patients With Dry AMD

Light therapy with multiple wavelengths may safely improve vision, reduce new retinal damage, and improve vision related quality of life in patients with dry age related macular degeneration.

Spanish Researchers Develop Low-cost Artificial Cornea From Fish Scales

Researchers at Spain's University of Granada have developed an artificial cornea made from the scales ⁠of several fish species commonly found in markets, which could become...

Todays Updates

T-DXd Reduces Residual Disease in Early Breast Cancer

Neoadjuvant trastuzumab deruxtecan combination therapy reduces the residual cancer burden in high-risk early breast cancer, even if a pathologic complete response is not achieved, shows analysis.

Todays Updates

T-DXd Reduces Residual Disease in Early Breast Cancer

Neoadjuvant trastuzumab deruxtecan combination therapy reduces the residual cancer burden in high-risk early breast cancer, even if a pathologic complete response is not achieved, shows analysis.

Latest News

The drug, reproxalap, led to reductions in symptoms of dry eye, but regulators have repeatedly refused to approve it for this condition.

Remission is achievable and relapses are uncommon in patients with sarcoid uveitis, although those with swelling in the macular region may experience delayed remission.

Women in academic ophthalmology earn less than men across all ranks, with a pay-gap over a full career of roughly $1 million, a study finds.

The U.S. Food and Drug Administration declined to approve Aldeyra Therapeutics' drug for a type ⁠of eye disease, the company said on Tuesday, sending its shares plunging...

Light therapy with multiple wavelengths may safely improve vision, reduce new retinal damage, and improve vision related quality of life in patients with dry age related macular degeneration.

Researchers at Spain's University of Granada have developed an artificial cornea made from the scales ⁠of several fish species commonly found in markets, which could become...

News All Time

Metabolic Syndrome Tied to Glaucoma Risk

Metabolic syndrome, rather than BMI or waist circumference, is linked to an increased likelihood of glaucoma and may better identify adults who could benefit from closer eye screening.

Two Biologics Show Comparable Benefit in Uveitis

Adalimumab and tocilizumab perform similarly in controlling inflammation while reducing the use of corticosteroids at week 16 in patients with refractory, noninfectious uveitis.

Ocular Therapeutix Plunges as Modest Benefit Overshadow Trial Win Over Regeneron's Eylea

Ocular Therapeutix's experimental eye drug showed superiority to Regeneron's Eylea in a key late-stage trial, but ⁠its modest advantage and higher rates of certain side...

Early Retinal Fluid Drying May Extend Injection Gaps in AMD

Rapid drying of retinal fluid with faricimab injections may help identify patients with neovascular age-related macular degeneration who can safely extend time between injections.

PDS Ranibizumab Retains Visual Acuity Gains in nAMD, with John Kitchens, MD John W. Kitchens, MD

The ongoing Archway-Portal extension study indicates the lasting efficacy and safety of ranibizumab dosing via the Port Delivery System.

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

The HCPFive: Top News for Healthcare Providers from the Week of 12/28

The HCPFive: Top News for Healthcare Providers from the Week of 12/28

FDA Issues Complete Response Letter for ONS-5010 for Wet AMD

FDA Issues Complete Response Letter for ONS-5010 for Wet AMD

Ophthalmology in 2025: Year in Review

Ophthalmology in 2025: Year in Review

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

6 Ophthalmology Headlines You Missed in October 2025

6 Ophthalmology Headlines You Missed in October 2025

New Parameters for Faster Geographic Atrophy Progression Established, with Srinivas Sadda, MD Srinivas Sadda, MD

The pooled sham cohorts of the OAKS and DERBY trials have revealed a series of indicators for faster geographic atrophy lesion growth.

OCU-410 Gene Therapy Preserves Visual Acuity and Slows GA Lesion Progression, with Jay Chhablani, MD Jay Chhablani, MD

Recent phase 1/2 trial data indicate the safety and efficacy of the surgical, subretinal injection in monitoring cellular homeostasis.

Intravitreal UBX1325 Shows Efficacy in Diabetic Retinopathy, DME, with Dante Pieramici, MD Dante J. Pieramici, MD

Results from the BEHOLD and ASPIRE trials indicate the long lasting effects of UBX1325 in improving retinal function and structure.

Recommended News For You

Sub-Q Ketamine is Safe and Very Effective for Severe Depression.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

Treatment of Smoldering Myeloma Cuts Progression Rate in Half

An FDA panel supports the use of CAR T-cell therapy earlier in the treatment of multiple myeloma.

Weight-Based and Fixed-Dose Pembrolizumab Compared in NSCLC

Chris Hoy reveals that he has terminal cancer?here's how to spot early signs of prostate cancer

The acceptance of innovative hormonal therapy for advanced prostate cancer is racialized.

Recommended Articles For You

Cancer-Keeper Genes: Novel Therapeutic Targets for Disrupting Tumor Maintenance 

The Precision Revolution: Bispecific Antibodies and Antibody-Drug Conjugates Reshaping the Oncology Landscape 

Navigating the Stages of Thyroid Cancer: A Guide for Patients 

Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

3D virtual staining technology enables non-invasive observation of cancer tissue

2.

Risk-Benefit Analysis of CAR-T Therapies for Myeloma is Muddy by Early Death Risk.

3.

BMI is linked to heart damage from chemotherapy in breast cancer patients.

4.

New Gene Therapy Nears EU Nod for Bladder Cancer

5.

Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.

1.

Future of Chemotherapy: New Advances, Treatments & Survival Rates Transforming Cancer Care

2.

Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma

3.

The Importance of Corrected Calcium Levels in Managing Health Conditions 

4.

The Power of Salt Tablets: Unlocking Health Benefits Beyond Sodium

5.

Radiation Oncology: Integrating AI, Theranostics, and Adaptive Therapies for Personalized Cancer Care

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

2.

Newer Immunotherapies for Myeloma- A Comprehensive Overview

3.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV

4.

Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot